美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

GRAIL, Inc.

139.89

+2.521.83%

成交量：34.65万

成交额：4,830.05万

市值：62.48亿

市盈率：-14.35

高：142.17

开：137.64

低：135.24

收：137.37

52周最高：166.48

52周最低：41.50

股本：4,466.62万

流通股本：4,072.79万

量比：0.39

换手率：0.85%

股息：- -

股息率：- -

每股收益(TTM):-9.7487

每股收益(LYR):-11.1105

净资产收益率：-16.12%

总资产收益率：-12.03%

市净率：2.46

市盈率(LYR):-12.59

数据加载中...

总览公司新闻资讯公告

受FDA和Medicare利好预期推动，TD Cowen将Grail的目标价上调逾一倍，该公司股价应声上涨

异动解读｜GRAIL盘中上涨5.56%，FDA顾问委员会积极评估催化延续

异动解读｜GRAIL盘中上涨5.14%，FDA顾问委员会积极评估催化延续

异动解读｜GRAIL盘前上涨6.76%，FDA顾问委员会利好催化延续

异动解读｜GRAIL盘中上涨5.13%，UBS大幅上调目标价至175美元

异动解读｜GRAIL盘中上涨6%，FDA顾问委员会利好催化延续推动股价反弹

Grail公司的癌症血液检测即将获得具有里程碑意义的FDA批准，但保险报销问题仍待解决

异动解读｜GRAIL盘中下跌5.07%，FDA顾问委员会利好消化后股价回调

异动解读｜GRAIL盘中上涨5.27%，FDA顾问委员会全票通过Galleri安全性并支持获批

异动解读｜GRAIL盘中上涨5.69%，FDA顾问委员会投票支持Galleri癌症检测获批

异动解读｜GRAIL盘中上涨5.97%，FDA顾问委员会投票支持Galleri癌症检测产品上市

券商观点：Grail癌症检测进展提振多癌种检测市场前景

媒体摘要-《华尔街日报》——9月24日

媒体摘要-《华尔街日报》——9月24日

美国食品药品监督管理局（FDA）顾问委员会认可Grail公司癌症检测的安全性，并以微弱优势认可其有效性

暗流涌动：GRAIL股价因FDA会议文件公布而飙升

FDA未对癌症检测提出重大担忧，Grail股价大涨

美国食品药品监督管理局将召开咨询会议，审议Grail公司的多癌种检测

GRAIL宣布FDA咨询委员会会议将审议Galleri®多癌早检上市前申请

Priority Health携手GRAIL，成为密歇根州首个为雇主计划提供Galleri®多癌种早期检测血液测试的医疗计划

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/GRAL/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRAL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":139.885,"timestamp":1791916233965,"preClose":137.37,"halted":0,"volume":346465,"delay":0,"changeRate":0.01830821867947868,"floatShares":40727891,"shares":44666200,"eps":-9.748709,"marketStatus":"交易中","change":2.515,"latestTime":"10-13 14:30:40 EDT","open":137.64,"high":142.17,"low":135.24,"amount":48300543.599350005,"amplitude":0.050448,"askPrice":139.88,"askSize":20,"bidPrice":139.64,"bidSize":121,"shortable":3,"etf":0,"ttmEps":-9.748709,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":137.37,"preHourTrading":{"tag":"盘前","latestPrice":137.64,"preClose":137.37,"latestTime":"09:29 EDT","volume":559,"amount":76655.40727,"timestamp":1791898199999,"change":0.27,"changeRate":0.001965,"amplitude":0.019},"postHourTrading":{"tag":"盘后","latestPrice":137.37,"preClose":137.37,"latestTime":"19:55 EDT","volume":10199,"amount":1400762.24,"timestamp":1791849343062,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.388651,"impliedVol":0.9433,"impliedVolPercentile":0.5697},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","floatShares":40727891,"roa":"-12.03%","roe":"-16.12%","lyrEps":-11.110457,"volumeRatio":0.388651,"shares":44666200,"dividePrice":0,"high":142.17,"amplitude":0.050448,"preClose":137.37,"low":135.24,"week52Low":41.5,"pbRate":"2.46","psRate":"37.81","week52High":166.475,"institutionHeld":0,"latestPrice":139.885,"committee":0.716312,"eps":-9.748709,"divideRate":0,"volume":346465,"delay":0,"ttmEps":-9.748709,"open":137.64,"prevYearClose":85.59,"prevWeekClose":140.58,"prevMonthClose":140.12,"prevQuarterClose":140.12,"fiveDayClose":137.28,"twentyDayClose":75.89,"sixtyDayClose":68.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRAL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"GRAL","fiscalQuarterEnding":"2026/06","expectedEps":-2.91,"name":null,"time":"盘后","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":-2.56},{"market":"US","date":"2026-05-05","symbol":"GRAL","fiscalQuarterEnding":"2026/03","expectedEps":3,"name":null,"time":"盘后","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"post","actualEps":-2.29},{"market":"US","date":"2026-02-19","symbol":"GRAL","fiscalQuarterEnding":"2025/12","expectedEps":-3.33,"name":null,"time":"盘后","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":-1.86},{"market":"US","date":"2025-11-12","symbol":"GRAL","fiscalQuarterEnding":"2025/09","expectedEps":-3.4,"name":null,"time":"盘后","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-2.46},{"market":"US","date":"2025-08-12","symbol":"GRAL","fiscalQuarterEnding":"2025/06","expectedEps":-3.14,"name":null,"time":"盘后","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-3.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRAL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRAL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.25,"hold":0.5833,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":12,"updateTime":1791604800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRAL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRAL","date":"2026-10-12","current":-14.392162,"percent":0.003578,"low":-17.575081,"twenty":-7.885385,"median":-2.735616,"eighty":-0.306797,"high":-0.135365,"avg":-4.003489,"sd":3.963384,"marketCap":6279179175},"quantilePoints":[{"date":"2024-06-12","current":-0.243184,"twenty":-0.243184,"median":-0.243184,"eighty":-0.243184,"marketCap":362571424},{"date":"2024-06-28","current":-0.269888,"twenty":-0.264547,"median":-0.256536,"eighty":-0.248525,"marketCap":402385270},{"date":"2024-07-05","current":-0.275763,"twenty":-0.275763,"median":-0.271757,"eighty":-0.266328,"marketCap":411144316},{"date":"2024-07-12","current":-0.259385,"twenty":-0.273627,"median":-0.266328,"eighty":-0.249504,"marketCap":386725157},{"date":"2024-07-15","current":-0.263657,"twenty":-0.273022,"median":-0.264992,"eighty":-0.25148,"marketCap":393095372},{"date":"2024-08-02","current":-0.296236,"twenty":-0.274909,"median":-0.266328,"eighty":-0.253456,"marketCap":441668264},{"date":"2024-08-09","current":-0.310656,"twenty":-0.300615,"median":-0.272114,"eighty":-0.260667,"marketCap":463167741},{"date":"2024-08-16","current":-0.170902,"twenty":-0.29588,"median":-0.2706,"eighty":-0.248276,"marketCap":492749978},{"date":"2024-08-23","current":-0.178117,"twenty":-0.292284,"median":-0.264992,"eighty":-0.180551,"marketCap":513552907},{"date":"2024-08-30","current":-0.159595,"twenty":-0.28292,"median":-0.259385,"eighty":-0.170708,"marketCap":460148373},{"date":"2024-09-06","current":-0.145057,"twenty":-0.275763,"median":-0.247457,"eighty":-0.162201,"marketCap":418232023},{"date":"2024-09-13","current":-0.145918,"twenty":-0.275336,"median":-0.18151,"eighty":-0.152854,"marketCap":420715955},{"date":"2024-09-20","current":-0.149365,"twenty":-0.273627,"median":-0.178117,"eighty":-0.150075,"marketCap":430651682},{"date":"2024-09-27","current":-0.146457,"twenty":-0.273022,"median":-0.170741,"eighty":-0.146026,"marketCap":422268412},{"date":"2024-10-04","current":-0.135365,"twenty":-0.270458,"median":-0.165733,"eighty":-0.14454,"marketCap":390287790},{"date":"2024-10-11","current":-0.140319,"twenty":-0.269176,"median":-0.160133,"eighty":-0.142925,"marketCap":404570398},{"date":"2024-10-18","current":-0.152918,"twenty":-0.265794,"median":-0.156041,"eighty":-0.143463,"marketCap":440897901},{"date":"2024-10-25","current":-0.13978,"twenty":-0.263443,"median":-0.155556,"eighty":-0.143463,"marketCap":403017941},{"date":"2024-10-31","current":-0.146672,"twenty":-0.262589,"median":-0.153942,"eighty":-0.142688,"marketCap":422889395},{"date":"2024-11-08","current":-0.160456,"twenty":-0.259385,"median":-0.152918,"eighty":-0.142796,"marketCap":462632305},{"date":"2024-11-15","current":-0.250879,"twenty":-0.250879,"median":-0.154641,"eighty":-0.143442,"marketCap":531228205},{"date":"2024-11-22","current":-0.259924,"twenty":-0.250879,"median":-0.156041,"eighty":-0.143549,"marketCap":550380645},{"date":"2024-11-29","current":-0.277697,"twenty":-0.262044,"median":-0.156472,"eighty":-0.143635,"marketCap":588013510},{"date":"2024-12-06","current":-0.355611,"twenty":-0.27003,"median":-0.160025,"eighty":-0.14426,"marketCap":752993300},{"date":"2024-12-13","current":-0.329745,"twenty":-0.275763,"median":-0.161318,"eighty":-0.144928,"marketCap":698224042},{"date":"2024-12-20","current":-0.271984,"twenty":-0.27776,"median":-0.165841,"eighty":-0.145746,"marketCap":575917232},{"date":"2024-12-27","current":-0.308005,"twenty":-0.287312,"median":-0.170741,"eighty":-0.145918,"marketCap":652190984},{"date":"2025-01-03","current":-0.284362,"twenty":-0.289787,"median":-0.175532,"eighty":-0.146134,"marketCap":602125834},{"date":"2025-01-10","current":-0.280236,"twenty":-0.294514,"median":-0.180594,"eighty":-0.1465,"marketCap":593389633},{"date":"2025-01-17","current":-0.276189,"twenty":-0.293978,"median":-0.222157,"eighty":-0.146801,"marketCap":584821436},{"date":"2025-01-24","current":-0.412102,"twenty":-0.295346,"median":-0.234852,"eighty":-0.147318,"marketCap":872612048},{"date":"2025-01-31","current":-0.500013,"twenty":-0.298484,"median":-0.241319,"eighty":-0.14818,"marketCap":1058760325},{"date":"2025-02-07","current":-0.523498,"twenty":-0.307212,"median":-0.249504,"eighty":-0.148826,"marketCap":1108489468},{"date":"2025-02-14","current":-0.83436,"twenty":-0.31102,"median":-0.255132,"eighty":-0.149365,"marketCap":1766728591},{"date":"2025-02-21","current":-0.791697,"twenty":-0.321747,"median":-0.260916,"eighty":-0.149365,"marketCap":1604772870},{"date":"2025-02-28","current":-0.656882,"twenty":-0.34371,"median":-0.263657,"eighty":-0.149709,"marketCap":1331502572},{"date":"2025-03-07","current":-0.559345,"twenty":-0.359577,"median":-0.270244,"eighty":-0.149795,"marketCap":1133795978},{"date":"2025-03-14","current":-0.450152,"twenty":-0.414561,"median":-0.273627,"eighty":-0.15014,"marketCap":912460022},{"date":"2025-03-21","current":-0.465034,"twenty":-0.450921,"median":-0.275763,"eighty":-0.150484,"marketCap":942626791},{"date":"2025-03-28","current":-0.47791,"twenty":-0.468947,"median":-0.276427,"eighty":-0.150807,"marketCap":968726130},{"date":"2025-04-04","current":-0.416039,"twenty":-0.465703,"median":-0.277856,"eighty":-0.15113,"marketCap":843313720},{"date":"2025-04-11","current":-0.380338,"twenty":-0.459122,"median":-0.280236,"eighty":-0.151281,"marketCap":770947370},{"date":"2025-04-17","current":-0.443129,"twenty":-0.455455,"median":-0.281347,"eighty":-0.151562,"marketCap":898224019},{"date":"2025-04-25","current":-0.630246,"twenty":-0.466372,"median":-0.283965,"eighty":-0.151863,"marketCap":1277511821},{"date":"2025-05-02","current":-0.565758,"twenty":-0.478944,"median":-0.287218,"eighty":-0.15253,"marketCap":1146794916},{"date":"2025-05-09","current":-0.62862,"twenty":-0.498389,"median":-0.292296,"eighty":-0.15337,"marketCap":1274216573},{"date":"2025-05-16","current":-0.732698,"twenty":-0.51302,"median":-0.295346,"eighty":-0.153995,"marketCap":1402606531},{"date":"2025-05-23","current":-0.728564,"twenty":-0.527433,"median":-0.296725,"eighty":-0.154728,"marketCap":1394692362},{"date":"2025-05-30","current":-0.772349,"twenty":-0.542338,"median":-0.298484,"eighty":-0.155417,"marketCap":1478510603},{"date":"2025-06-06","current":-0.742094,"twenty":-0.562722,"median":-0.305137,"eighty":-0.155977,"marketCap":1420593278},{"date":"2025-06-13","current":-0.787758,"twenty":-0.602918,"median":-0.308322,"eighty":-0.156041,"marketCap":1508008868},{"date":"2025-06-20","current":-0.910282,"twenty":-0.617043,"median":-0.310838,"eighty":-0.156127,"marketCap":1742556049},{"date":"2025-06-27","current":-0.927946,"twenty":-0.628237,"median":-0.313683,"eighty":-0.156967,"marketCap":1776371133},{"date":"2025-07-03","current":-0.87796,"twenty":-0.640897,"median":-0.324667,"eighty":-0.158949,"marketCap":1680681639},{"date":"2025-07-11","current":-0.815382,"twenty":-0.656882,"median":-0.33641,"eighty":-0.159595,"marketCap":1560889904},{"date":"2025-07-18","current":-0.675007,"twenty":-0.694504,"median":-0.351643,"eighty":-0.160456,"marketCap":1292167904},{"date":"2025-07-25","current":-0.746416,"twenty":-0.703946,"median":-0.35847,"eighty":-0.160672,"marketCap":1428867181},{"date":"2025-08-01","current":-0.642872,"twenty":-0.704698,"median":-0.372061,"eighty":-0.161318,"marketCap":1230653229},{"date":"2025-08-08","current":-0.619382,"twenty":-0.703946,"median":-0.384644,"eighty":-0.164764,"marketCap":1185686362},{"date":"2025-08-15","current":-2.618835,"twenty":-0.718416,"median":-0.412102,"eighty":-0.165733,"marketCap":1160018171},{"date":"2025-08-22","current":-2.697774,"twenty":-0.721799,"median":-0.415789,"eighty":-0.165949,"marketCap":1194984536},{"date":"2025-08-29","current":-2.7759,"twenty":-0.732698,"median":-0.419718,"eighty":-0.170579,"marketCap":1229590423},{"date":"2025-09-05","current":-2.733582,"twenty":-0.742958,"median":-0.427076,"eighty":-0.170837,"marketCap":1210845568},{"date":"2025-09-12","current":-3.145369,"twenty":-0.751941,"median":-0.435395,"eighty":-0.172539,"marketCap":1393247431},{"date":"2025-09-19","current":-3.221867,"twenty":-0.757193,"median":-0.443129,"eighty":-0.177083,"marketCap":1427132362},{"date":"2025-09-26","current":-3.927439,"twenty":-0.772199,"median":-0.450236,"eighty":-0.179927,"marketCap":1739666779},{"date":"2025-10-03","current":-5.267781,"twenty":-0.790326,"median":-0.453995,"eighty":-0.180724,"marketCap":2333374029},{"date":"2025-10-10","current":-5.788618,"twenty":-0.792794,"median":-0.466707,"eighty":-0.18193,"marketCap":2564079942},{"date":"2025-10-17","current":-7.032117,"twenty":-0.810572,"median":-0.474733,"eighty":-0.214168,"marketCap":3114890311},{"date":"2025-10-24","current":-6.726125,"twenty":-0.834423,"median":-0.483801,"eighty":-0.232186,"marketCap":2979350587},{"date":"2025-10-31","current":-7.417862,"twenty":-0.86879,"median":-0.497307,"eighty":-0.23482,"marketCap":3285756878},{"date":"2025-11-07","current":-6.515349,"twenty":-0.90953,"median":-0.508594,"eighty":-0.23627,"marketCap":2885986787},{"date":"2025-11-14","current":-7.32206,"twenty":-1.284423,"median":-0.515869,"eighty":-0.238888,"marketCap":3243320953},{"date":"2025-11-21","current":-8.218834,"twenty":-2.622741,"median":-0.524768,"eighty":-0.242438,"marketCap":3338827399},{"date":"2025-11-28","current":-10.592844,"twenty":-2.668803,"median":-0.533066,"eighty":-0.245748,"marketCap":4303247596},{"date":"2025-12-05","current":-10.047321,"twenty":-2.733908,"median":-0.545714,"eighty":-0.248685,"marketCap":4081633659},{"date":"2025-12-12","current":-9.121802,"twenty":-2.773947,"median":-0.559678,"eighty":-0.249586,"marketCap":3705650118},{"date":"2025-12-19","current":-8.474563,"twenty":-3.023948,"median":-0.565758,"eighty":-0.250383,"marketCap":3442715024},{"date":"2025-12-26","current":-8.814736,"twenty":-3.115583,"median":-0.600672,"eighty":-0.254281,"marketCap":3580907004},{"date":"2026-01-02","current":-8.213077,"twenty":-3.191837,"median":-0.607471,"eighty":-0.259493,"marketCap":3336488466},{"date":"2026-01-09","current":-9.407758,"twenty":-3.756539,"median":-0.615248,"eighty":-0.260321,"marketCap":3821817142},{"date":"2026-01-16","current":-9.350183,"twenty":-4.63773,"median":-0.618067,"eighty":-0.262044,"marketCap":3798427809},{"date":"2026-01-23","current":-11.136928,"twenty":-5.050494,"median":-0.621638,"eighty":-0.262589,"marketCap":4524276801},{"date":"2026-01-30","current":-9.689876,"twenty":-5.381714,"median":-0.623725,"eighty":-0.263657,"marketCap":3936424878},{"date":"2026-02-06","current":-9.025844,"twenty":-5.92371,"median":-0.62862,"eighty":-0.266328,"marketCap":3666667895},{"date":"2026-02-13","current":-9.201448,"twenty":-6.490935,"median":-0.634416,"eighty":-0.269888,"marketCap":3738005363},{"date":"2026-02-20","current":-10.027753,"twenty":-6.738169,"median":-0.640672,"eighty":-0.270458,"marketCap":4094842980},{"date":"2026-02-27","current":-5.738328,"twenty":-6.59852,"median":-0.642551,"eighty":-0.271707,"marketCap":2343252016},{"date":"2026-03-06","current":-5.1161,"twenty":-6.525603,"median":-0.645131,"eighty":-0.273298,"marketCap":2089164448},{"date":"2026-03-13","current":-4.454105,"twenty":-6.495818,"median":-0.656882,"eighty":-0.273627,"marketCap":1818838106},{"date":"2026-03-20","current":-4.868977,"twenty":-6.467497,"median":-0.678025,"eighty":-0.275336,"marketCap":1988251759},{"date":"2026-03-27","current":-5.23965,"twenty":-6.370491,"median":-0.694504,"eighty":-0.275763,"marketCap":2139616500},{"date":"2026-04-02","current":-5.384303,"twenty":-6.22661,"median":-0.703946,"eighty":-0.276019,"marketCap":2198685668},{"date":"2026-04-10","current":-4.777565,"twenty":-6.012578,"median":-0.718792,"eighty":-0.276332,"marketCap":1950923327},{"date":"2026-04-17","current":-4.969431,"twenty":-5.842655,"median":-0.720859,"eighty":-0.277189,"marketCap":2029272014},{"date":"2026-04-24","current":-5.087966,"twenty":-5.758444,"median":-0.724241,"eighty":-0.277697,"marketCap":2077675915},{"date":"2026-05-01","current":-5.472702,"twenty":-5.73481,"median":-0.732698,"eighty":-0.277887,"marketCap":2234783492},{"date":"2026-05-08","current":-6.830613,"twenty":-5.758444,"median":-0.740497,"eighty":-0.278585,"marketCap":2700312031},{"date":"2026-05-15","current":-6.709025,"twenty":-6.393277,"median":-0.747877,"eighty":-0.279728,"marketCap":2652245447},{"date":"2026-05-22","current":-7.366901,"twenty":-6.535065,"median":-0.752054,"eighty":-0.280426,"marketCap":2912320000},{"date":"2026-05-29","current":-8.024776,"twenty":-6.608933,"median":-0.75506,"eighty":-0.280871,"marketCap":3172394554},{"date":"2026-06-05","current":-7.224687,"twenty":-6.675155,"median":-0.757458,"eighty":-0.282109,"marketCap":2856099264},{"date":"2026-06-12","current":-6.530986,"twenty":-6.667338,"median":-0.770188,"eighty":-0.283378,"marketCap":2581862234},{"date":"2026-06-18","current":-6.453909,"twenty":-6.64758,"median":-0.774322,"eighty":-0.283727,"marketCap":2551391453},{"date":"2026-06-26","current":-7.226858,"twenty":-6.705551,"median":-0.790201,"eighty":-0.284901,"marketCap":2856957596},{"date":"2026-07-02","current":-7.394041,"twenty":-6.741593,"median":-0.791697,"eighty":-0.287059,"marketCap":2923049149},{"date":"2026-07-10","current":-8.227784,"twenty":-6.830613,"median":-0.793866,"eighty":-0.287218,"marketCap":3252648583},{"date":"2026-07-17","current":-7.811998,"twenty":-6.920316,"median":-0.805047,"eighty":-0.287691,"marketCap":3088278032},{"date":"2026-07-24","current":-7.638301,"twenty":-7.010823,"median":-0.819893,"eighty":-0.291185,"marketCap":3019611483},{"date":"2026-07-31","current":-7.722978,"twenty":-7.028862,"median":-0.830133,"eighty":-0.292962,"marketCap":3053086426},{"date":"2026-08-07","current":-7.231699,"twenty":-7.225121,"median":-0.842819,"eighty":-0.294422,"marketCap":2831839235},{"date":"2026-08-14","current":-7.783772,"twenty":-7.278539,"median":-0.870399,"eighty":-0.295212,"marketCap":3048023808},{"date":"2026-08-21","current":-8.893621,"twenty":-7.372329,"median":-0.87796,"eighty":-0.295699,"marketCap":3482626264},{"date":"2026-08-28","current":-9.410334,"twenty":-7.428129,"median":-0.917705,"eighty":-0.296146,"marketCap":3684964305},{"date":"2026-09-04","current":-9.195892,"twenty":-7.480979,"median":-0.966282,"eighty":-0.297019,"marketCap":3600991785},{"date":"2026-09-11","current":-8.846854,"twenty":-7.492831,"median":-2.572448,"eighty":-0.297976,"marketCap":3464313109},{"date":"2026-09-18","current":-9.119469,"twenty":-7.639447,"median":-2.628601,"eighty":-0.298484,"marketCap":3571065408},{"date":"2026-09-25","current":-14.282035,"twenty":-7.746291,"median":-2.668477,"eighty":-0.301515,"marketCap":5592659159},{"date":"2026-10-02","current":-15.12041,"twenty":-7.801576,"median":-2.688619,"eighty":-0.304496,"marketCap":5920955979},{"date":"2026-10-09","current":-15.126113,"twenty":-7.871629,"median":-2.734396,"eighty":-0.306382,"marketCap":5923189290},{"date":"2026-10-12","current":-16.035208,"twenty":-7.885385,"median":-2.735616,"eighty":-0.306797,"marketCap":6279179175}],"updateTime":1791912949484},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRAL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2675651003","title":"受FDA和Medicare利好预期推动，TD Cowen将Grail的目标价上调逾一倍，该公司股价应声上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2675651003","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675651003?lang=zh_cn&edition=fundamental","pubTime":"2026-10-14 00:09","pubTimestamp":1791907766,"startTime":"0","endTime":"0","summary":"BUZZ-受FDA和Medicare利好预期推动，TD Cowen将Grail的目标价上调逾一倍，该公司股价应声上涨10月13日-** Grail（GRAL.O）股价上涨逾2%，至140.53美元** TD Cowen将这家癌症检测厂商的目标价从88美元上调至180美元——较上一交易日收盘价有31%的上行空间；维持“买入”评级** 该券商在FDA咨询委员会会议后，将GRAL旗下Galleri早期癌","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nL4T45Z1P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169929282","title":"异动解读｜GRAIL盘中上涨5.56%，FDA顾问委员会积极评估催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1169929282","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169929282?lang=zh_cn&edition=fundamental","pubTime":"2026-10-09 21:39","pubTimestamp":1791553182,"startTime":"0","endTime":"0","summary":"10月9日，GRAIL盘中上涨5.56%，报138.66美元/股，成交额667.56万美元。消息面上，FDA分子与临床遗传学器械顾问委员会对Galleri多癌种早检产品的积极投票结果持续发酵，资本市场连续多日反映该催化效应。PATHFINDER 2研究亦显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。尽管顾问委员会意见对FDA不具约束力，最终审批结果仍待公布，但市场情绪已明显偏向乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"癌症早检获FDA积极评估，GRAIL盘中上扬","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197444992","title":"异动解读｜GRAIL盘中上涨5.14%，FDA顾问委员会积极评估催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1197444992","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197444992?lang=zh_cn&edition=fundamental","pubTime":"2026-10-06 21:34","pubTimestamp":1791293671,"startTime":"0","endTime":"0","summary":"10月6日，GRAIL盘中上涨5.14%，报166.0美元/股，成交额1666.97万美元。消息面上，FDA分子与临床遗传学器械顾问委员会对Galleri多癌种早检产品的积极投票结果持续发酵，资本市场连续多日反映该催化效应。此前公布的结果显示，Galleri安全性以10:0全票通过，有效性6:4通过，获益风险7:2通过。尽管顾问委员会意见对FDA不具约束力，最终审批结果仍待公布，但市场情绪已明显偏向乐观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GRAIL盘中大涨，FDA积极评估持续催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178518451","title":"异动解读｜GRAIL盘前上涨6.76%，FDA顾问委员会利好催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1178518451","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178518451?lang=zh_cn&edition=fundamental","pubTime":"2026-10-06 17:18","pubTimestamp":1791278329,"startTime":"0","endTime":"0","summary":"10月6日，GRAIL盘前上涨6.76%，报156.93美元/股，成交额16.27万美元。此前FDA分子与临床遗传学器械顾问委员会对Galleri投票结果积极：安全性10:0全票通过，有效性6:4通过，获益风险7:2通过。PATHFINDER 2研究亦显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。尽管顾问委员会意见对FDA不具约束力，最终审批结果仍待公布，但资本市场已连续多日反映该催化效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA利好持续发酵，GRAIL盘前冲高","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116494514","title":"异动解读｜GRAIL盘中上涨5.13%，UBS大幅上调目标价至175美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116494514","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116494514?lang=zh_cn&edition=fundamental","pubTime":"2026-10-05 23:53","pubTimestamp":1791215598,"startTime":"0","endTime":"0","summary":"10月5日，GRAIL盘中上涨5.13%，报150.61美元/股，成交额5011.85万美元。消息面上，瑞银最新将GRAIL目标价从105美元大幅上调至175美元，维持买入评级。此次异动延续了9月下旬以来FDA顾问委员会对Galleri多癌种早检产品的积极评估催化效应——此前委员会投票中安全性10:0全票通过，获益风险7:2通过。需注意FDA最终审批仍需等待正式结果公布。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153892212","title":"异动解读｜GRAIL盘中上涨6%，FDA顾问委员会利好催化延续推动股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1153892212","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153892212?lang=zh_cn&edition=fundamental","pubTime":"2026-10-02 21:47","pubTimestamp":1790948837,"startTime":"0","endTime":"0","summary":"10月2日，GRAIL盘中上涨6%，报140.38美元/股，成交额941.74万美元。此前盘中曾因短期获利回吐一度走低，随后快速反弹。消息面上，FDA分子与临床遗传学器械顾问委员会此前对GRAIL旗下Galleri多癌种早检产品投票结果积极——安全性10:0全票通过、有效性6:4通过、获益风险7:2通过。PATHFINDER 2研究显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。需注意，顾问委员会意见对FDA不具约束力，最终正式审批结果仍待公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA利好催化延续，GRAIL盘中上涨6%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672711329","title":"Grail公司的癌症血液检测即将获得具有里程碑意义的FDA批准，但保险报销问题仍待解决","url":"https://stock-news.laohu8.com/highlight/detail?id=2672711329","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672711329?lang=zh_cn&edition=fundamental","pubTime":"2026-10-02 19:47","pubTimestamp":1790941646,"startTime":"0","endTime":"0","summary":"Grail公司的癌症血液检测即将获得具有里程碑意义的FDA批准，但保险报销问题仍待解决Sneha S K/Kamal Choudhury路透10月2日-上周，美国食品和药物管理局的一个咨询小组为Grail公司的GRAL.OGalleri血液检测项目赢得了一场里程碑式的胜利，该小组表示，这项早期癌症检测的潜在益处大于其风险，这使该检测离获批又近了一步。根据今年通过的一项美国法律，若获得FDA批准，这些检测自2028年起将有资格纳入“联邦医疗保险”的报销范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nL4S45O0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158000170","title":"异动解读｜GRAIL盘中下跌5.07%，FDA顾问委员会利好消化后股价回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1158000170","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158000170?lang=zh_cn&edition=fundamental","pubTime":"2026-10-02 03:55","pubTimestamp":1790884530,"startTime":"0","endTime":"0","summary":"10月2日，GRAIL盘中下跌5.07%，报133.01美元/股，成交额1.17亿美元。消息面上，此前FDA分子与临床遗传学器械顾问委员会对旗下Galleri多癌种早检产品投票结果积极——安全性10:0全票通过、有效性6:4通过、获益风险7:2通过，推动股价自9月下旬以来大幅走高。随着顾问委员会催化逐步被市场消化，短期获利回吐压力显现。顾问委员会意见对FDA不具约束力，最终正式审批结果仍待公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"GRAIL股价回落，FDA利好消化后承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100526236","title":"异动解读｜GRAIL盘中上涨5.27%，FDA顾问委员会全票通过Galleri安全性并支持获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1100526236","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100526236?lang=zh_cn&edition=fundamental","pubTime":"2026-09-30 22:07","pubTimestamp":1790777220,"startTime":"0","endTime":"0","summary":"消息面上，FDA分子与临床遗传学器械顾问委员会此前就GRAIL旗下Galleri多癌种早期检测产品的上市前批准申请进行投票，10名委员以10:0全票通过安全性，6:4通过有效性，7:2认定该产品对50岁及以上成人的临床获益大于风险。此前PATHFINDER 2研究显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。瑞银维持买入评级，认为顾问委员会的积极投票几乎\"消除了风险\"，市场对Galleri正式获批的预期持续升温，推动股价自9月下旬以来大幅走高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA顾问委员会全票通过，GRAIL上涨","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194948486","title":"异动解读｜GRAIL盘中上涨5.69%，FDA顾问委员会投票支持Galleri癌症检测获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1194948486","media":"行情直击","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194948486?lang=zh_cn&edition=fundamental","pubTime":"2026-09-28 21:45","pubTimestamp":1790603132,"startTime":"0","endTime":"0","summary":"9月28日，GRAIL盘中上涨5.69%，报130.765美元/股，成交额1775.57万美元。消息面上，FDA分子与临床遗传学器械顾问委员会近日对GRAIL旗下Galleri多癌种早期检测产品的上市前批准申请进行投票，10名投票成员全票通过安全性，以6比4通过有效性，以7比2通过针对50岁及以上成人的获益-风险评估。顾问委员会的积极投票进一步推动市场对Galleri正式获批的乐观预期，股价延续近期上行趋势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA顾问委员会支持，GRAIL盘中上涨","news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199948635","title":"异动解读｜GRAIL盘中上涨5.97%，FDA顾问委员会投票支持Galleri癌症检测产品上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1199948635","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199948635?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 21:58","pubTimestamp":1790258310,"startTime":"0","endTime":"0","summary":"消息面上，FDA医疗器械咨询委员会分子与临床遗传学设备小组对Galleri多癌种早期检测产品的上市前批准申请进行了投票，10名投票成员全票通过其安全性，以6比4支持其有效性，以7比2认可其在50岁及以上成人中检测多种癌症的获益-风险比。此前FDA简报文件显示，该机构对Galleri的分析性能、桥接分析及主要安全性数据无重大疑问，讨论焦点集中在产品标签定位上。顾问委员会的积极投票为后续FDA正式批准奠定了重要基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA顾问委员会力挺，GRAIL盘中上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669616214","title":"券商观点：Grail癌症检测进展提振多癌种检测市场前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2669616214","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669616214?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 18:09","pubTimestamp":1790244580,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：Grail癌症检测进展提振多癌种检测市场前景9月24日-** 癌症检测公司Grail（GRAL.O）周三获得了美国食品药品监督管理局（FDA）外部专家顾问小组的支持（(link)），这为该检测在癌症筛查领域获得可能具有里程碑意义的批准铺平了道路** 专家小组以7票赞成、2票反对、1票弃权的表决结果认定，这款名为Galleri的检测手段能够发现难以检测的癌症，因此适用于50岁及以","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4T45G0RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669545139","title":"媒体摘要-《华尔街日报》——9月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2669545139","media":"路透中文","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669545139?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 13:22","pubTimestamp":1790227324,"startTime":"0","endTime":"0","summary":"媒体摘要-《华尔街日报》——9月24日9月24日-以下是《华尔街日报》的头条新闻。路透尚未核实这些报道，也不对其准确性作任何担保。- 澳大利亚总理安东尼·阿尔巴内塞周三在纽约举行的联合国会议上表示，今年夏天，一个OpenAI智能体  成功渗透进澳大利亚的一个政府服务网站。- 佛罗里达州高速铁路运营商  Brightline计划近期在新泽西州申请第11章破产保护，以重组约55亿美元的债务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4S45G0D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","ODDZ","BK4561","MGM","GRAL","BK4011","KNF","LU0566484027.USD","BK4150","BK4585","BK4139","LU1559883803.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669393451","title":"媒体摘要-《华尔街日报》——9月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2669393451","media":"路透中文","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669393451?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 13:22","pubTimestamp":1790227324,"startTime":"0","endTime":"0","summary":"媒体摘要-《华尔街日报》——9月24日9月24日-以下是《华尔街日报》的头条新闻。路透尚未核实这些报导，也不对其准确性作任何担保。- 澳大利亚总理安东尼·阿尔巴内塞周三在纽约举行的联合国会议上表示，今年夏天，一个OpenAI智能体  成功渗透进澳大利亚的一个政府服务网站。- 佛罗里达州高速铁路运营商  Brightline计划近期在新泽西州申请第11章破产保护，以重组约55亿美元的债务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4T45G0D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1559883803.SGD","BK4011","LU0566484027.USD","BK4585","BK4150","BK4561","LU1571399168.USD","MGM","KNF","BK4588","ODDZ","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669431821","title":"美国食品药品监督管理局（FDA）顾问委员会认可Grail公司癌症检测的安全性，并以微弱优势认可其有效性","url":"https://stock-news.laohu8.com/highlight/detail?id=2669431821","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669431821?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 05:43","pubTimestamp":1790199792,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）顾问委员会认可Grail公司癌症检测的安全性，并以微弱优势认可其有效性路透9月23日-周三，一个为美国食品药品监督管理局（FDA）提供咨询的外部专家小组认可了Grail公司GRAL.O的血液癌症检测试剂盒“Galleri”的安全性，但小组成员对支持其有效性的证据存在分歧。虽然所有10名小组成员都认可“Galleri”的安全性，但对其有效性的支持则较为有限，最终以6票赞成、4票反对的结果通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL4T45F1HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134221217","title":"暗流涌动：GRAIL股价因FDA会议文件公布而飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=1134221217","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134221217?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 06:58","pubTimestamp":1790031507,"startTime":"0","endTime":"0","summary":"周一，GRAIL公司股价大幅攀升34%，此轮涨势源于美国食品药品监督管理局在周四顾问委员会会议前夕发布了一系列文件。这些文件将对FDA是否批准该公司研发的多癌种血液检测产品起到决定性作用。自2021年起，GRAIL便以处方形式销售此产品，但FDA至今尚未批准任何一款用于筛查多种癌症的检测手段。然而，该检测对多数癌症病例未能及时发现。无论是上述美国研究，还是在涉及约14.2万人的英国试验中，Galleri仅能捕捉到约三分之一在一年内确诊的癌症病例。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4139","GRAL","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164485","title":"FDA未对癌症检测提出重大担忧，Grail股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164485","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164485?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 23:48","pubTimestamp":1790005685,"startTime":"0","endTime":"0","summary":"BUZZ-FDA未对癌症检测提出重大担忧，Grail股价大涨9月21日-** 癌症检测公司Grail（GRAL.O）股价上涨34.6%，升至108.71美元，创下七个月以来新高** 美国食品药品监督管理局（FDA）发布简报文件，显示Grail公司的Galleri多癌种筛查检测未存在重大安全或技术问题** FDA专家小组讨论主要聚焦于产品标签，以及现有数据是否足以支持明确的“早期检测”宣称** 加拿","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4T45D14T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","LU0053671581.USD","BK4139","GRAL","PIPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657491642","title":"美国食品药品监督管理局将召开咨询会议，审议Grail公司的多癌种检测","url":"https://stock-news.laohu8.com/highlight/detail?id=2657491642","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657491642?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 23:11","pubTimestamp":1786115470,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局将召开咨询会议，审议Grail公司的多癌种检测路透8月7日-Grail公司GRAL.O周五表示，美国食品药品监督管理局（FDA）计划于9月召开一次外部专家会议，对其多癌种筛查检测Galleri进行评审。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL4S4441AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180134132","title":"GRAIL宣布FDA咨询委员会会议将审议Galleri®多癌早检上市前申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1180134132","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180134132?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 23:06","pubTimestamp":1786115182,"startTime":"0","endTime":"0","summary":"GRAIL（股票代码：GRAL）正式对外披露，美国食品药品监督管理局（FDA）已计划召开一场咨询委员会会议，专门针对其旗下面向多癌种早期检测的Galleri®检测产品，所提交的上市前批准申请（PMA）进行深入审议。这一里程碑式的进展，标志着该潜在颠覆性癌症筛查技术，在通往监管绿灯的道路上，迈出了至关重要的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191676874","title":"Priority Health携手GRAIL，成为密歇根州首个为雇主计划提供Galleri®多癌种早期检测血液测试的医疗计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1191676874","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191676874?lang=zh_cn&edition=fundamental","pubTime":"2026-07-16 21:01","pubTimestamp":1784206891,"startTime":"0","endTime":"0","summary":"Priority Health与GRAIL, Inc.达成合作，开创密歇根州先河，成为该州首个将Galleri®多癌种早期检测血液测试纳入雇主医疗计划的健康保险机构。此项合作旨在通过前沿的液体活检技术，为参保员工提供更早发现多种癌症的机会，从而可能改善治疗结果并降低医疗成本。Galleri®测试能够通过单次抽血，筛查出50多种癌症的信号，其中包括许多缺乏常规筛查指南的癌症类型。这一举措标志着精准医疗和预防性健康管理在雇主福利领域的重要拓展，有望提升整体人群的健康水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}